The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Background An improvement in progression-free survival was shown with trastuzumab
deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast …

Background In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan
showed robust activity in patients with HER2-positive metastatic breast cancer who were …

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that
currently combines the selectivity of monoclonal antibodies with the potency of a payload …

Abstract Background Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity
in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has …

Abstract The AURORA US Metastasis Project was established with the goal to identify
molecular features associated with metastasis. We assayed 55 females with metastatic …

Breast cancer heterogeneity determines cancer progression, treatment effects, and
prognosis. However, the precise mechanism for this heterogeneity remains unknown owing …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …